McKesson Corporation released its 2025 Corporate Responsibility Report on October 29, 2024, detailing the company’s progress toward its environmental, social, and governance (ESG) goals for the previous fiscal year. The …
Tag:
Oncology
-
-
Integrative oncology programs that offer insurance-covered symptom management provide significant clinical benefits for cancer patients, according to research published in the Journal of the National Comprehensive Cancer Network. By incorporating …
-
Researchers are identifying new approaches to BET protein inhibitors, targeting a class of epigenetic regulators that have historically proven difficult to drug effectively in solid tumors. By shifting from traditional …
-
Lung cancer tumors can trigger cancer cachexia—a wasting syndrome characterized by severe muscle loss—by hijacking the nervous system to suppress immune responses and degrade muscle tissue. According to research linked …
-
Circulating tumor DNA (ctDNA) analysis is emerging as a precise tool for identifying which patients with colorectal cancer (CRC) are most likely to benefit from adjuvant chemotherapy. By detecting minimal …
-
The Relationship Between Allergies and Cancer Risk: Examining the Immunological Evidence Research into the link between allergies and cancer suggests that the body’s immune response may play a dual role …
-
New research indicates that combining targeted therapies with immunotherapy significantly improves clinical outcomes for patients with advanced, treatment-resistant melanoma. According to findings published in the Journal of Clinical Oncology, patients …
-
Stockholm3 Blood Test Detects 90% of Aggressive Prostate Cancers, Study Shows A new blood test called Stockholm3 has demonstrated the ability to detect 90% of high-risk prostate cancers. The test …
-
Peptide-Based mRNA Vaccine Demonstrates 70% Tumor Shrinkage in Neuroblastoma Trials A peptide-based mRNA vaccine showed significant promise in reducing neuroblastoma tumors by 70% in early clinical trials, according to a …
-
Myriad Genetics has expanded the clinical availability of its Precise MRD™ test, a molecular residual disease (MRD) assay designed to detect circulating tumor DNA (ctDNA) in patients with solid tumors. …
Newer Posts